Inspection Record

BWXT Medical Ltd. — Health Canada Inspection Findings

Health CanadaInspected 2024-04-08 11 findingsStability and storageDeviation, CAPA, and investigationOther quality systemMaterial and supplier controlEquipment and facilityContamination controlQuality unit oversightAseptic processing and sterility assuranceLaboratory and QC controls

View the regulator's official source The source document is always the basis for judgement.

Findings

1Stability and storage

The guidelines and/or procedures were inadequate in ensuring storage and/or transportation conditions would maintain the quality and safe distribution of the drug. The temperature and/or humidity control was inadequate.

2Deviation, CAPA, and investigation

The investigation, handling, and/or reporting of test results that were out-of-specification was inadequate. The company's monitoring of water testing was inadequate. The operation of the water purification equipment was inadequate for ensuring a reliable source of water.

3Other quality system

The traceability, legibility, documentation, formatting, and/or the accuracy of records was inadequate.

4Material and supplier control

The sampling plan for raw materials was inadequate. Each container of a lot of raw materials was not tested to identify its contents with a specific, discriminating test.

5Equipment and facility

The preventative maintenance program was inadequate for the equipment used in significant processing and/or testing operations.

6Other quality system

The receipt, preparation, and/or handling of reagents and culture media was inadequate.

7Equipment and facility

The availability, content and/or maintenance of the quality agreements between the supplier, fabricator, tester, packager, labeller, distributor, importer, and/or wholesaler was inadequate.

8Contamination control

The sanitation programs were not adequately designed to identify and/or reduce the risks of contamination.

9Quality unit oversight

The annual product quality review procedure was inadequate.

10Aseptic processing and sterility assurance

For sterile drugs, the stability program did not include a confirmation of sterility at the initial testing and at the end of the drug's shelf life. The ongoing stability program for a drug was inadequate.

11Laboratory and QC controls

The creation, maintenance, processing, and/or review of laboratory data was inadequate.

About this record

Extracted automatically from the document of the Health Canada inspection on 2024-04-08. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Other records for this company

BWXT Medical Ltd. company profile — full history Health Canada documents, 2024 Go to Findings search